Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 March 2014Next earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 04 Oct 2024 23:31:11 GMTDividend
Analysts recommendations
Institutional Ownership
PCSA Latest News
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap).
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
Clinical-stage pharmaceutical company Processa Therapeutics (NASDAQ: PCSA ) — which specializes in the field of oncology — is skyrocketing on Thursday. PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate overview at the Biotech Showcase 2024. The event is being held at the Hilton San Francisco Union Square on January 8 – 10, 2024.
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that CEO George Ng will present an updated corporate overview at the ThinkEquity Conference. The conference is being held on October 19, 2023 at the Mandarin Oriental Hotel in New York.
HANOVER, MD, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that David Young, President of Research and Development, will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on August 16 – 17, 2023.
What type of business is Processa Pharmaceuticals?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
What sector is Processa Pharmaceuticals in?
Processa Pharmaceuticals is in the Healthcare sector
What industry is Processa Pharmaceuticals in?
Processa Pharmaceuticals is in the Biotechnology industry
What country is Processa Pharmaceuticals from?
Processa Pharmaceuticals is headquartered in United States
When did Processa Pharmaceuticals go public?
Processa Pharmaceuticals initial public offering (IPO) was on 07 March 2014
What is Processa Pharmaceuticals website?
https://www.processapharmaceuticals.com
Is Processa Pharmaceuticals in the S&P 500?
No, Processa Pharmaceuticals is not included in the S&P 500 index
Is Processa Pharmaceuticals in the NASDAQ 100?
No, Processa Pharmaceuticals is not included in the NASDAQ 100 index
Is Processa Pharmaceuticals in the Dow Jones?
No, Processa Pharmaceuticals is not included in the Dow Jones index
When was Processa Pharmaceuticals the previous earnings report?
No data
When does Processa Pharmaceuticals earnings report?
The next expected earnings date for Processa Pharmaceuticals is 13 November 2024